Showing 3891-3900 of 5910 results for "".
- Ikerian and RetinAI Secure $8M Financing to Drive AI Healthcare Innovationhttps://modernod.com/news/ikerian-and-retinai-secure-8m-financing-to-drive-ai-healthcare-innovation/2482494/Switzerland-based Ikerian AG and its subsidiary RetinAI US, announced the successful first close of their Series B financing round, securing USD $8 million (CHF 6.73 million). With the newly secured funding, Ikerian said it is set to fast-track the development of its flagship produ
- Ocular Therapeutix Announces Accelerated Timelines for SOL-1 Registrational Trial of Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-accelerated-timelines-for-sol-1-registrational-trial-of-axpaxli-in-wet-amd/2482490/Ocular Therapeutix announced an acceleration of the SOL-1 phase 3 registrational clinical trial of Axpaxli for wet age-related macular degeneration (wet AMD). The company now expects to complete enrollment and randomization by the end of 2024, ahead of previous guidance to finish by the first qua
- Oculis to Provide Update on DIAMOND Phase 3 Program for OCS-01 Eye Drops at Innovate Retina and Eyecelerator 2024https://modernod.com/news/oculis-to-provide-update-on-diamond-phase-3-program-for-ocs-01-eye-drops-at-innovate-retina-and-eyecelerator-2024/2482488/Oculis announced an update on its DIAMOND phase 3 program for OCS-01, a high-concentration dexamethasone eye drop formulated with OPTIREACH technology for the treatment for diabetic macular edema (DME). David Eichenbaum, MD, an expert in retina diseases, will present new insig
- Centricity Vision Unveils Enhancements to ZEPTOLink IOL Positioning System at AAO 2024https://modernod.com/news/centricity-vision-unveils-enhancements-to-zeptolink-iol-positioning-system-at-aao-2024/2482487/Centricity Vision announced platform enhancements for its ZEPTOLink IOL Positioning System designed to reduce treatment time by up to 60%. The enhancements will be highlighted at the American Academy of Ophthalmology (AAO) annual meeting, taking place from October 18-21, 2024, in Chicago.
- Heidelberg Engineering Receives FDA Clearance for Spectralis Flex Module for Supine Imaginghttps://modernod.com/news/heidelberg-engineering-receives-fda-clearance-for-spectralis-flex-module-for-supine-imaging/2482486/Heidelberg Engineering has received FDA clearance for its Spectralis Flex Module, a multimodal diagnostic imaging platform. The new module is designed specifically for imaging the posterior segment of both pediatric and adult patients in a supine position, addressing a need for patients unab
- RetinaLyze Launches Advanced Glaucoma Progression AIhttps://modernod.com/news/retinalyze-launches-advanced-glaucoma-progression-ai/2482480/RetinaLyze has introduced the Advanced Glaucoma Progression AI. Central to this technology is the 'Glaucoma Index of Progression' (GIP), a tool designed to provide a stable and consistent method for tracking glaucoma progression over time. Glaucoma, often referred to a
- Melt Announces Completion of Patient Dosing in Phase 3 Study of MELT-300 for Procedural Sedationhttps://modernod.com/news/melt-pharmaceuticals-announces-completion-of-patient-dosing-in-phase-3-study-of-melt-300-for-procedural-sedation/2482477/Melt Pharmaceuticals announced the completion of patient dosing in its pivotal phase 3 clinical trial. This study evaluates the safety and efficacy of MELT-300, the company's lead product candidate, for providing non-intravenous, non-opioid sedation during cataract surgery. MELT-300
- Nanoscope Therapeutics Plans to Submit BLA for Gene Therapy to Treat RPhttps://modernod.com/news/nanoscope-therapeutics-plans-to-submit-bla-for-gene-therapy-to-treat-retinitis-pigmentosa/2482476/Nanoscope Therapeutics has announced a successful meeting with the FDA regarding its lead clinical program, MCO-010, for the treatment of retinitis pigmentosa (RP). Following regulatory feedback from the FDA, the company plans to initiate a rolling submission of its biologics license ap
- Clearside Biomedical Reports Positive Results from Phase 2b ODYSSEY Trial of CLS-AX for Wet AMDhttps://modernod.com/news/clearside-biomedical-reports-positive-results-from-phase-2b-odyssey-trial-of-cls-ax-for-wet-amd/2482475/Clearside Biomedical announced that its phase 2b ODYSSEY trial of CLS-AX (axitinib injectable suspension) for the treatment of wet age-related macular degeneration (AMD) achieved its primary and all secondary endpoints. In the trial, patients treated with suprachoroidal CLS-AX show
- Cure Blindness Project Unveils Global Expansion Plan on World Sight Dayhttps://modernod.com/news/cure-blindness-project-unveils-global-expansion-plan-on-world-sight-day/2482471/In honor of World Sight Day on October 10, the non-profit Cure Blindness Project announced an expansion plan that will extend its sight-restoring services to six new countries: Burundi, Democratic Republic of the Congo, Liberia, Pakistan, Paraguay, and Zambia. This move marks the organi